EV-103

Enfortumab Vedotin Trial
in Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Cancer (Cohort K)

EV-103
PHASE 1b/2
CLINICAL TRIAL

NOW ENROLLING

ev103

Enfortumab Vedotin Trial
in Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Cancer (Cohort K)

EV-103
PHASE 1b/2
CLINICAL TRIAL

NOW ENROLLING

EV-103
Enfortumab Vedotin Trial
in Urothelial Carcinoma

EV-103: A Clinical Trial for the Treatment of Urothelial Cancer

Cohort K: Enfortumab vedotin (EV) alone or in combination with pembrolizumab in first line cisplatin-eligible subjects with locally advanced or metastatic urothelial cancer

WHO MAY BE ELIGIBLE TO TAKE PART?	TREATMENT	MAIN MEASURE
People with urothelial cancer that cannot be removed with surgery or has spread to other parts of the body	EV + pembrolizumab or EV	The number of people who had their tumors shrink or had no detectable tumors

Who may qualify for this Study?

EV-103 Cohort K is for:

- People who are 18 years or older
- People with locally advanced or metastatic urothelial cancer that cannot be completely removed with surgery
- People who have not yet received any oral or intravenous treatment for their locally advanced or metastatic urothelial cancer
- People who are not able to receive a type of chemotherapy called cisplatin
- People who have never received a checkpoint inhibitor [treatments such as KEYTRUDA® (pembrolizumab), OPDIVO® (nivolumab), TECENTRIQ® (atezolizumab), Bavencio® (avelumab), IMFINZI® (durvalumab), YERVOY (ipilimumab)]

This is not a complete list of criteria for participation

If you are a person recently diagnosed with urothelial cancer, consider learning more about the EV-103 study:

- Contact Seagen Trial Information Support 866-333-7436
- Discuss with your doctor — bring this postcard to your next visit
- Visit: https://clinicaltrials.gov/ct2/show/NCT03288545
- Visit: https://bit.ly/3vJS9Kg

Additional information:

- If you enroll into this study, you may receive reimbursement for approved travel expenses associated with participating in the study.
- Your cancer prognosis may or may not improve by taking part in the EV-103 study.
- People who are in the study may decide to stop at any time.

About the Study

Participants in this study will be randomly assigned to receive either EV alone or EV in combination with pembrolizumab. This is an open-label study, which means both the study doctor and the participant will know the treatment the participant is receiving.

- Participants who take part in the study will receive EV as an infusion into a vein (also called "IV") 2 times during a 21-day cycle (on Day 1 and Day 8)
- Participants who take part in the study who also get pembrolizumab will receive it as an infusion into a vein (also called "IV") once every 21-day cycle (on Day 1)

What is the purpose of this Study?

The purpose of this study is to find out if EV in combination with pembrolizumab works as the first treatment for patients with locally advanced or metastatic urothelial cancer. To do that, this study will look at:

- The number of participants whose tumors have gotten smaller on scans
- How long it takes for cancer to spread or get worse after the beginning of treatment with EV in combination with pembrolizumab
- How long participants live after the beginning of treatment

This is not a complete list of outcomes that will be observed in this clinical study

The use of enfortumab vedotin (EV) and pembrolizumab described here is experimental. Because of that, not all risks are known. People who are in the study may decide to stop at any time.

Seagen®